Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by First Western Trust Bank

First Western Trust Bank trimmed its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 10.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,867 shares of the medical research company's stock after selling 1,353 shares during the period. Thermo Fisher Scientific accounts for about 0.3% of First Western Trust Bank's investment portfolio, making the stock its 23rd biggest holding. First Western Trust Bank's holdings in Thermo Fisher Scientific were worth $7,341,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Strengthening Families & Communities LLC boosted its holdings in Thermo Fisher Scientific by 5.9% during the third quarter. Strengthening Families & Communities LLC now owns 4,880 shares of the medical research company's stock worth $3,019,000 after purchasing an additional 271 shares during the last quarter. Aviso Wealth Management raised its position in Thermo Fisher Scientific by 113.9% during the third quarter. Aviso Wealth Management now owns 3,414 shares of the medical research company's stock worth $2,112,000 after acquiring an additional 1,818 shares in the last quarter. GLOBALT Investments LLC GA grew its stake in shares of Thermo Fisher Scientific by 5.0% in the third quarter. GLOBALT Investments LLC GA now owns 1,102 shares of the medical research company's stock valued at $682,000 after acquiring an additional 52 shares in the last quarter. Glass Wealth Management Co LLC grew its stake in shares of Thermo Fisher Scientific by 4.3% in the third quarter. Glass Wealth Management Co LLC now owns 4,562 shares of the medical research company's stock valued at $2,822,000 after acquiring an additional 190 shares in the last quarter. Finally, Claro Advisors LLC grew its stake in shares of Thermo Fisher Scientific by 75.3% in the third quarter. Claro Advisors LLC now owns 1,299 shares of the medical research company's stock valued at $804,000 after acquiring an additional 558 shares in the last quarter. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock traded down $12.83 during trading hours on Monday, reaching $500.25. 2,266,758 shares of the stock traded hands, compared to its average volume of 1,477,021. The company has a 50 day moving average price of $586.43 and a 200 day moving average price of $582.39. The firm has a market capitalization of $191.35 billion, a price-to-earnings ratio of 32.17, a P/E/G ratio of 3.39 and a beta of 0.79. Thermo Fisher Scientific Inc. has a one year low of $465.90 and a one year high of $627.88. The company has a quick ratio of 1.26, a current ratio of 1.63 and a debt-to-equity ratio of 0.64.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, topping analysts' consensus estimates of $5.25 by $0.03. The company had revenue of $10.60 billion for the quarter, compared to analysts' expectations of $10.63 billion. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The firm's revenue was up .2% compared to the same quarter last year. During the same period in the previous year, the firm earned $5.69 EPS. On average, equities research analysts expect that Thermo Fisher Scientific Inc. will post 21.67 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, January 15th. Stockholders of record on Friday, December 13th will be given a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.31%. The ex-dividend date is Friday, December 13th. Thermo Fisher Scientific's payout ratio is 9.78%.

Thermo Fisher Scientific declared that its Board of Directors has authorized a share repurchase plan on Friday, November 15th that permits the company to repurchase $4.00 billion in outstanding shares. This repurchase authorization permits the medical research company to repurchase up to 2% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company's board believes its shares are undervalued.

Analysts Set New Price Targets

TMO has been the subject of several analyst reports. Stifel Nicolaus lowered their price target on shares of Thermo Fisher Scientific from $680.00 to $665.00 and set a "buy" rating for the company in a report on Thursday, October 24th. Bernstein Bank lifted their price target on shares of Thermo Fisher Scientific from $565.00 to $625.00 and gave the company a "market perform" rating in a research report on Tuesday, October 22nd. Bank of America lifted their price objective on shares of Thermo Fisher Scientific from $600.00 to $675.00 and gave the stock a "buy" rating in a report on Monday, September 16th. Raymond James boosted their price objective on Thermo Fisher Scientific from $650.00 to $660.00 and gave the company an "outperform" rating in a research note on Thursday, July 25th. Finally, JPMorgan Chase & Co. boosted their price objective on Thermo Fisher Scientific from $650.00 to $670.00 and gave the company an "overweight" rating in a research note on Friday, September 20th. Four analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Thermo Fisher Scientific has an average rating of "Moderate Buy" and an average target price of $649.33.

Insider Transactions at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 9,000 shares of the company's stock in a transaction on Friday, November 8th. The stock was sold at an average price of $552.86, for a total transaction of $4,975,740.00. Following the completion of the sale, the chief executive officer now directly owns 14,608 shares in the company, valued at $8,076,178.88. This represents a 38.12 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, SVP Michael A. Boxer sold 2,000 shares of the company's stock in a transaction on Friday, October 25th. The stock was sold at an average price of $560.16, for a total value of $1,120,320.00. Following the sale, the senior vice president now owns 12,736 shares of the company's stock, valued at $7,134,197.76. This trade represents a 13.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 37,150 shares of company stock valued at $20,651,865. 0.34% of the stock is currently owned by corporate insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.